BACKGROUND AIMS: Donor-derived vertebral bone marrow (BM) has been proposed to promote chimerism in solid organ transplantation with cadaveric organs. Reports of successful weaning from immunosuppression in patients receiving directed donor transplants in combination with donor BM or blood cells and novel peri-transplant immunosuppression has renewed interest in implementing similar protocols with cadaveric organs. METHODS: We performed six pre-clinical full-scale separations to adapt vertebral BM preparations to a good manufacturing practice (GMP) environment. Vertebral bodies L4-T8 were transported to a class 10 000 clean room, cleaned of soft tissue, divided and crushed in a prototype bone grinder. Bone fragments were irrigated with medium containing saline, albumin, DNAse and gentamicin, and strained through stainless steel sieves. Additional cells were eluted after two rounds of agitation using a prototype BM tumbler. RESULTS: The majority of recovered cells (70.9 ± 14.1%, mean ± SD) were eluted directly from the crushed bone, whereas 22.3% and 5.9% were eluted after the first and second rounds of tumbling, respectively. Cells were pooled and filtered (500, 200 μm) using a BM collection kit. Larger lumbar vertebrae yielded about 1.6 times the cells of thoracic vertebrae. The average product yielded 5.2 ± 1.2 × 10(10) total cells, 6.2 ± 2.2 × 10(8) of which were CD45(+) CD34(+). Viability was 96.6 ± 1.9% and 99.1 ± 0.8%, respectively. Multicolor flow cytometry revealed distinct populations of CD34(+) CD90(+) CD117(dim) hematopoietic stem cells (15.5 ± 7.5% of the CD34 (+) cells) and CD45(-) CD73(+) CD105(+) mesenchymal stromal cells (0.04 ± 0.04% of the total cells). CONCLUSIONS: This procedure can be used to prepare clinical-grade cells suitable for use in human allotransplantation in a GMP environment.
BACKGROUND AIMS: Donor-derived vertebral bone marrow (BM) has been proposed to promote chimerism in solid organ transplantation with cadaveric organs. Reports of successful weaning from immunosuppression in patients receiving directed donor transplants in combination with donor BM or blood cells and novel peri-transplant immunosuppression has renewed interest in implementing similar protocols with cadaveric organs. METHODS: We performed six pre-clinical full-scale separations to adapt vertebral BM preparations to a good manufacturing practice (GMP) environment. Vertebral bodies L4-T8 were transported to a class 10 000 clean room, cleaned of soft tissue, divided and crushed in a prototype bone grinder. Bone fragments were irrigated with medium containing saline, albumin, DNAse and gentamicin, and strained through stainless steel sieves. Additional cells were eluted after two rounds of agitation using a prototype BM tumbler. RESULTS: The majority of recovered cells (70.9 ± 14.1%, mean ± SD) were eluted directly from the crushed bone, whereas 22.3% and 5.9% were eluted after the first and second rounds of tumbling, respectively. Cells were pooled and filtered (500, 200 μm) using a BM collection kit. Larger lumbar vertebrae yielded about 1.6 times the cells of thoracic vertebrae. The average product yielded 5.2 ± 1.2 × 10(10) total cells, 6.2 ± 2.2 × 10(8) of which were CD45(+) CD34(+). Viability was 96.6 ± 1.9% and 99.1 ± 0.8%, respectively. Multicolor flow cytometry revealed distinct populations of CD34(+) CD90(+) CD117(dim) hematopoietic stem cells (15.5 ± 7.5% of the CD34 (+) cells) and CD45(-) CD73(+) CD105(+) mesenchymal stromal cells (0.04 ± 0.04% of the total cells). CONCLUSIONS: This procedure can be used to prepare clinical-grade cells suitable for use in human allotransplantation in a GMP environment.
Authors: P Fontes; A S Rao; J Reyes; H Furukawa; K Abu-Elmagd; N Jabbour; A Zeevi; A Iyengar; S Todo; J J Fung; T E Starzl Journal: Transplant Proc Date: 1996-10 Impact factor: 1.066
Authors: A S Rao; D Phil; P Fontes; A Iyengar; A Aitouche; R Shapiro; A Zeevi; F Dodson; R Corry; C Rastellini; J J Fung; T E Starzl Journal: Adv Exp Med Biol Date: 1997 Impact factor: 2.622
Authors: N Murase; Q Ye; M A Nalesnik; A J Demetris; K Abu-Elmagd; J Reyes; N Ichikawa; T Okuda; J J Fung; T E Starzl Journal: Transplantation Date: 2000-12-15 Impact factor: 4.939
Authors: T E Starzl; A J Demetris; M Trucco; N Murase; C Ricordi; S Ildstad; H Ramos; S Todo; A Tzakis; J J Fung Journal: Hepatology Date: 1993-06 Impact factor: 17.425
Authors: P Fontes; A S Rao; A J Demetris; A Zeevi; M Trucco; P Carroll; W Rybka; W A Rudert; C Ricordi; F Dodson Journal: Lancet Date: 1994-07-16 Impact factor: 79.321
Authors: Erika Moravcikova; E Michael Meyer; Mirko Corselli; Vera S Donnenberg; Albert D Donnenberg Journal: Cytometry A Date: 2018-09-13 Impact factor: 4.355
Authors: Albert D Donnenberg; Vijay S Gorantla; Stefan Schneeberger; Linda R Moore; Gerald Brandacher; Heather M Stanczak; Eileen K Koch; Wp Andrew Lee Journal: Regen Med Date: 2011-11 Impact factor: 3.806
Authors: Stefan Schneeberger; Vijay S Gorantla; Gerald Brandacher; Adriana Zeevi; Anthony J Demetris; John G Lunz; Diana M Metes; Albert D Donnenberg; Jaimie T Shores; Andrea F Dimartini; Joseph E Kiss; Joseph E Imbriglia; Kodi Azari; Robert J Goitz; Ernest K Manders; Vu T Nguyen; Damon S Cooney; Galen S Wachtman; Jonathan D Keith; Derek R Fletcher; Camila Macedo; Raymond Planinsic; Joseph E Losee; Ron Shapiro; Thomas E Starzl; W P Andrew Lee Journal: Ann Surg Date: 2013-02 Impact factor: 12.969
Authors: Martha L Bustos; Luai Huleihel; Ernest M Meyer; Albert D Donnenberg; Vera S Donnenberg; Joseph D Sciurba; Lyle Mroz; Bryan J McVerry; Bryon M Ellis; Naftali Kaminski; Mauricio Rojas Journal: Stem Cells Transl Med Date: 2013-10-02 Impact factor: 6.940
Authors: Matthias Waldner; Wensheng Zhang; Isaac B James; Kassandra Allbright; Emmanuelle Havis; Jacqueline M Bliley; Aurora Almadori; Riccardo Schweizer; Jan A Plock; Kia M Washington; Vijay S Gorantla; Mario G Solari; Kacey G Marra; J Peter Rubin Journal: Front Immunol Date: 2018-07-24 Impact factor: 7.561
Authors: Prakash N Rao; Dayanand D Deo; Misty A Marchioni; Rouzbeh R Taghizadeh; Kyle Cetrulo; Sharyn Sawczak; Jacob Myrick Journal: Stem Cells Int Date: 2019-11-25 Impact factor: 5.443
Authors: Erik J Woods; Aubrey M Sherry; John R Woods; James W Hardin; Michael LaFontaine; Gerald Brandacher; Brian H Johnstone Journal: J Transl Med Date: 2020-08-05 Impact factor: 5.531
Authors: Brian H Johnstone; Hannah M Miller; Madelyn R Beck; Dongsheng Gu; Sreedhar Thirumala; Michael LaFontaine; Gerald Brandacher; Erik J Woods Journal: Cytotherapy Date: 2020-08-30 Impact factor: 5.414